Background: Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, significantly reduces low-density lipoprotein cholesterol, but requires subcutaneous injections rather than oral pills. To measure patients' acceptance of this treatment modality, a new patient-reported outcome, the Injection-Treatment Acceptance Questionnaire (I-TAQ), was developed. Objectives: To psychometrically evaluate the I-TAQ with patients at high risk of cardiovascular events receiving alirocumab. Methods: The 22-item, 5-domain I-TAQ was administered cross-sectionally to 151 patients enrolled in alirocumab clinical trials. Item response distributions, factor and multitrait analyses, interitem correlations, correlations with an existing measure of acceptance (convergent validity), and comparison of knowngroups were performed to assess the I-TAQ's psychometric properties. Results: Completion rates were high, with no patients missing more than two items and 91.4% missing no data. All items displayed high ceiling effects (430%) because of high treatment acceptance. Factor analysis supported the a priori hypothesized item-domain structure with good fit indices (root mean square error approximation ¼ 0.070; comparative fit index ¼ 0.988) and high factor loadings. All items demonstrated item convergent validity (item-scale correlation Z0.40), except for the side effects domain, which was limited by small numbers (n ¼ 46). Almost all items correlated most highly with the domain to which they were assigned (item discriminant validity). Internal reliability was acceptable for all domains (Cronbach α range 0.72-0.88) and convergent validity was supported by a logical pattern of correlations with the Chronic Treatment Acceptance Questionnaire. Conclusions: These findings provide initial evidence of validity and reliability for the I-TAQ in patients treated with subcutaneous alirocumab. The I-TAQ could prove to be a valuable patient-reported outcome for therapies requiring subcutaneous injection.
Introduction
Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with an increased risk of cardiovascular (CV) events [1] , occurring in more than 2 million Americans each year and accounting for approximately one-quarter of total inpatient costs [2] . Lowering LDL-C levels with statin and nonstatin lipid-modifying therapies [3] reduces the risk of CV events [4] . Alirocumab is a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 that is administered via subcutaneous injection for the treatment of elevated LDL-C levels. Alirocumab has demonstrated significant incremental reduction in LDL-C levels with or without background statin therapy [5] [6] [7] [8] [9] .
Given the requirement for subcutaneous, as opposed to oral, administration, there is a need to assess patients' acceptance of the subcutaneous treatment approach. Accordingly, a novel patient-reported outcome (PRO) instrument, the Injection-Treatment Acceptance Questionnaire (I-TAQ), was developed to measure treatment acceptance. The concepts generated from a literature and instrument review informed the initial drafting of a 17-item version of the I-TAQ. Content validity, as outlined in the Food and Drug Administration PRO guidance [10] , was then assessed through three successive rounds of qualitative interviews conducted with 29 US-English-speaking patients who were participating in the phase III program for alirocumab. Each round of interviews included both concept elicitation (to ensure no important or relevant concepts were missing) and cognitive debriefing activities (to provide further evidence of relevance and ensure the items were well understood), the results of which informed revisions to the measure, resulting in a 22-item I-TAQ with established content validity [11] .
Once the content validity of the I-TAQ was established, an evaluation of the instrument's psychometric properties was required to evaluate reliability and validity in measuring patients' acceptance of subcutaneous treatments. The primary objective of this study, therefore, was to evaluate the psychometric properties of the I-TAQ to finalize the conceptual framework, evaluate the appropriateness of the a priori hypothesized scoring algorithm, and establish its validity and reliability.
Methods

Study Design
This was a multicenter, non-interventional, cross-sectional study to psychometrically validate the I-TAQ. The 22-item I-TAQ as well as two other PROs used for convergent validity, the Chronic Treatment Acceptance Questionnaire (ACCEPT) and a patient global impression of acceptance (PGI-A) measure, were all administered at one time point to each participant. The analyses are presented in Figure 1 . The appropriateness of the a priori conceptual framework and the scoring algorithm were evaluated through the examination of item-level statistics and dimensionality analyses. Then, the resulting measure and the scoring algorithm were subject to psychometric validation to evaluate the validity and reliability of the established scores.
The study was conducted in accordance with the Declaration of Helsinki and was overseen by a centralized independent review board in the United States (ethical approval reference: ADE1-14-383). Written informed consent was obtained from all participants before the collection of any data and before any study-related activities.
Patient Recruitment
All 151 patients were enrolled in alirocumab phase III trials and were recruited for participation in this observational study through 11 clinical sites in the United States. All patients were diagnosed with elevated LDL-C levels and were 18 years or older. The inclusion criteria required all patients to have experience of self-administering alirocumab (or placebo) via prefilled pen or prefilled syringe. Patients self-injecting alirocumab (or placebo), either as a single 1-ml dose every 2 weeks or two 1-ml doses every 4 weeks, were considered eligible for the study.
Data Collection
PRO measures
Injection-Treatment Acceptance Questionnaire. The I-TAQ is a 22-item, self-administered questionnaire, developed as a measure of treatment acceptance in patients who inject their medications via subcutaneous injections (Appendix A). The I-TAQ assesses five domains of treatment acceptance: perceived Fig. 1 -Overview of study analyses. V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] -] ] ] efficacy (items 1 and 2, the patient's perception of whether their treatment is working), acceptance of side effects (items 3-7, 11, and 12), injection self-efficacy (items 8-10, the ability of the patient to perform the task asked of them, e.g., self-injection), injection convenience (items [13] [14] [15] [16] [17] [18] [19] , and overall acceptance (items 20-22). All items have a 4-week recall period and are answered on a 5-point verbal descriptor scale, with the exception of items 3 (side effects) and 11 (pain), which use "yes/no" dichotomous response options. Items 3 and 11 are gateway items that allow patients to skip non-relevant items associated with side effects or pain.
Chronic Treatment Acceptance Questionnaire. The ACCEPT is a 32-item, self-administered questionnaire designed to assess long-term acceptance of a wide range of long-term medications. The items are organized into six domains: drug characteristics (items 1-5), duration (items 6 and 7), constraints (items 8-18), side effects (items 19-24), efficacy (items 25-28), and global acceptance (items 29-32). A recall period is not specified. With the exception of the four-item global acceptance domain, all items are answered on a 3-point adjectival response scale, and when relevant, a "not applicable" response option is included. The four items in the global acceptance domain employ a 5-point adjectival response scale.
PGI-A measure. A PGI-A was created for this study, comprising a single item asking patients to rate their total experience of using the study treatment on a 10-point scale, ranging from "very unacceptable" (1) to "very acceptable" (10) .
Statistical Analyses
All items in the I-TAQ were scored from 0 to 4, with 0 indicating low acceptance and 4 indicating high acceptance. Three items measuring interference of side effects were reverse-scored to ensure that the direction of scoring was consistent for all analyses.
Item-level and dimensionality analyses
Item-level and dimensionality analyses ( Fig. 1 ) were conducted to evaluate the appropriateness of the a priori conceptual framework and the hypothesized scoring algorithm for the I-TAQ.
Level of missing data. Missing data levels were assessed and any item with a substantial amount of missing data (defined a priori as 430%) was considered for deletion.
Item response distributions. Item response distributions and
floor and ceiling effects were examined for each item, including whether any item met the criteria for maximum endorsement frequencies (480% of responses in a particular category) or aggregate adjacent endorsement frequencies (two or more adjacent response categories on an item showing o10% of responses). Items with any overly favored response options or substantial floor or ceiling effects (420% of patients selecting the best or worst possible response for an item) were flagged for further consideration.
Use of skip patterns. Data from patients who incorrectly followed the skip patterns (i.e., answered the items they should have skipped according to their response to the gateway item) were analyzed separately, in addition to the total sample.
Inter-item correlations and factor analysis. Inter-item correlations were assessed and items with particularly high inter-item correlations (40.80) were considered in terms of potential redundancy. Confirmatory factor analysis (CFA) was conducted to evaluate the fit with the hypothesized five-domain framework (perceived efficacy, acceptance of side effects, injection selfefficacy, injection convenience, and overall acceptance). Model fit was assessed by calculating the comparative fit index (CFI; 40.95 for evidence of good fit [12] ), root mean square error approximation (RMSEA; o0.08 for acceptable fit [12] ), and modification indices. The weighted least squares with mean and variance adjustment (WLSMV) method of estimation was used to analyze polychoric correlations. Although there was an a priori hypothesized conceptual framework, exploratory factor analysis (EFA) was also performed to evaluate whether any alternative item-domain grouping might emerge. Crawford-Ferguson (CF) quartimax (equivalent to direct quartimin in oblique rotation) was used for the rotation method in the EFA. For both CFA and EFA, items with standardized coefficients of less than 0.30 would be flagged as candidates for possible deletion. It is also noteworthy that the WLSMV method of estimation used for EFA and CFA models employed a "pairwise present" approach to missingness where "limited information" from pairs of variables (itempairs) was used. The analyses were conducted using MPlus (Muthén & Muthén, Los Angeles, CA), which used all individuals with observations on that item-pair to derive the point estimates. Thus, all available observations were used to estimate each correlation, that is, the sample size varied for each correlation. This is important to note in relation to the side effects items, because those items were effectively missing for patients who did not experience side effects, resulting in much smaller sample sizes for the correlations involving those items.
Internal consistency. Internal reliability analyses (Cronbach α 40.70 being considered as a threshold for defining high internal reliability) were conducted to assess the homogeneity of items belonging to the same subscale or multi-item domain.
Item reduction process
The psychometric validation results were discussed during a daylong, face-to-face item reduction meeting that included as participants all the authors: two health outcomes researchers, three PRO developers, and an expert clinician who also had experience of developing PRO instruments. During the item reduction meeting, the conceptual relevance (informed by previous qualitative research findings [11] ) and clinical importance of items were considered alongside the results of the item response and dimensionality analyses described earlier. As such, the face and content validity of the items was given equal consideration as the initial psychometric findings when considering item deletion: an item considered important conceptually was not deleted on the basis of psychometric findings alone. A scoring algorithm and recommendations on how to treat missing data in the calculation of the I-TAQ total score were then defined, as described in the Results section. Following the development of the scoring algorithm, the psychometric properties of the resulting I-TAQ scores were assessed.
Psychometric evaluation analyses
Construct validity of the final measure was evaluated through assessment of CFA, multitrait analysis, convergent validity (examining correlations with other existing instruments), and known-groups analysis.
CFA and EFA. CFA was conducted again to confirm whether the I-TAQ items fit within the final conceptual framework. EFA was also performed to verify whether any other item-domain structure might provide better fit. Fit statistics and factor loading thresholds expected for CFA and EFA were as described in an earlier section, as was the rotation method used in the EFA.
Multitrait analysis. Multitrait analysis was conducted using
Pearson correlation coefficients to examine item-scale correlations, corrected for overlap (i.e., each item was correlated with its own scale, but with the item score removed first). Two criteria were considered: item convergent validity (the correlation coefficient between each item and its own domain [with the item removed] should be at least 0.40 [13, 14] ) and item discriminant validity (each item should correlate more highly with its own domain [with the item removed] than with any other domain [13, 14] ).
Convergent validity. Scale-level convergent validity was eval-
uated by examining the correlations of the I-TAQ domain scores with the scores of the ACCEPT measure. Correlations of more than 0.40 were expected among domains measuring similar concepts, and correlations of less than 0.40 were expected among domains measuring dissimilar concepts. Details of the specific domains that were hypothesized to correlate more than 0.40 are provided in Appendix B.
Known-groups analysis. The known-groups method was used to evaluate differences in scores among patients who differed on the following identified variables: type of diagnosis (e.g., hereditary familial hypercholesterolemia (HeFH) vs. non-HeFH), severity of CV risk (e.g., high risk vs. very high risk), mode of administration (e.g., prefilled pen vs. prefilled syringe), and overall treatment acceptance on the PGI-A. It was expected that because HeFH is a genetic condition, those patients may have higher treatment acceptance of a subcutaneous treatment, and patients at very high risk of CV events may also have a higher acceptance because of the increased perceived benefit of treatment. It was expected that patients who have a high overall acceptance on the PGI-A would also report high acceptance scores on the I-TAQ and patients using a prefilled pen would report higher acceptance than those using a prefilled syringe. All these analyses, however, were considered exploratory, because it was not possible to postulate a priori how closely treatment acceptance would be related to these parameters. Group comparisons were performed using t tests under the condition of normal distributions being validated.
All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC) apart from factor analyses, which were performed using Mplus version 7.11 (Muthén & Muthén, Los Angeles, CA), and multitrait analysis, which was performed using MAP-R for Windows, version 1.0 [13] .
Results
Demographic and Clinical Characteristics
Most of the patients (74.2%) included in the study administered their treatment using a prefilled pen. The mean age was 63 Ϯ 10.9 years and 64.9% (n ¼ 53) were male (Table 1) . Approximately a third of the patients (n ¼ 51; 33.8%) had been diagnosed with HeFH, three-quarter of whom had been diagnosed for more than 8 years. Just less than half of the patients (n ¼ 70; 46.4%) were deemed to be at very high risk of CV events, with a similar proportion at high risk (n ¼ 68; 45%) [15] . More than half of the patients were taking a high-potency statin in addition to alirocumab (n ¼ 84; 55.6%).
Item-Level and Initial Dimensionality Results
Level of missing data
Levels of missing data for the I-TAQ were low with no patients missing more than two items and 91.4% completing all items. In addition, no individual items were missed by more than 6.6% (n ¼ 10) of the patients. 
Item response distributions
The responses for items were positively skewed, indicating high levels of acceptance, and all items demonstrated ceiling effects (420% of patients providing the best possible response). The side effect items (although completed by only those experiencing side effects; n ¼ 20 [13%]) displayed the highest ceiling effects (80-90% scoring at ceiling), meeting the criteria for maximum endorsement frequencies. Several other items also had very high ceiling effects with more than 50% of the patients choosing the highest possible response (items 8-10, 13-16, and 18-21). All items had very few patients scoring at the floor (Appendix C). In addition, because of the skewed nature of the data, several items met the criteria for aggregate adjacent endorsement frequencies.
Use of skip patterns
Of the 131 patients who reported no side effects, 26 (17.2%) answered "no" to item 3, yet continued to answer items 4 to 7 (i.e., failing to follow the instruction that they should skip those items). Of the 132 patients who reported no pain, 10 (6.6%) patients answered "no" to item 11, but answered item 12 (i.e., incorrectly responded to the item they were instructed to skip).
Inter-item correlations
Inter-item correlations were examined (Appendix D). Excluding the side effects items, which were all highly correlated, five itempairs correlated above the a priori threshold (40.80), suggesting potential redundancy. Nevertheless, when the item content of each pair was examined alongside the results of the qualitative content validity study [11] , all were considered conceptually distinct. The side effects items were all highly correlated with each other (r ¼ 0.84-0.98), most likely in part because of the ceiling effects and small sample size completing the items (n ¼ 20)
. Although the content of some of the items was closely related, none of the concepts measured were considered sufficiently redundant in light of the previous qualitative findings [11] to support deletion. In addition, the supportive factor analysis results (described later), the concepts being assessed, and the skewed data, the inter-item correlations were not considered sufficient evidence to warrant deletion of any of these items at this time.
Calculation of Cronbach α for each domain with each item removed in turn
Calculation of Cronbach α for each domain with each item removed in turn suggested that only two items, if removed, would result in a very minor increase in the overall consistency of the scales. Specifically, item 12 from the acceptance of side effects domain (Cronbach α increased from 0.75 to 0.81) and item 10 from the injection self-efficacy domain (Cronbach α increased from 0.71 to 0.72) were flagged, but as the increase in internal consistency was very minor, this was not considered an adequate basis for deletion.
CFA five-factor results
Results of the CFA supported the hypothesized five-factor structure (Appendix E). It is noteworthy that items 3 ("do you have side effects") and 11 ("do you have pain") were not included in the analysis because they were gateway items, and the side effects items 5, 6, and 7 were removed due to the small sample size that completed those items. For the resulting five-factor solution, standardized factor loadings demonstrated all items loaded strongly onto their hypothesized domain (40.70), with 12 items loading onto their respective domain at 0.80 or higher. The overall acceptance domain correlated highly with all other domains with the exception of side effects (perceived efficacy ¼ 0.72; injection self-efficacy ¼ 0.71; injection convenience ¼ 0.83). Otherwise, correlations among factors were generally small to moderate, ranging from 0.02 (between perceived efficacy and acceptance of side effects) and 0.83 (between injection selfefficacy and injection convenience). Model fit indices demonstrated acceptable model fit (RMSEA ¼ 0.065; CFI ¼ 0.985). In the EFA, three factors had eigenvalues higher than 1, but the scree plot was considered to level out between four and five factors (Appendix F). The five-factor solution provided the best account of the data and mirrored the a priori conceptual framework, with all but four items loading onto their respective factor at higher than 0.70.
Item Reduction and Development of Scoring Algorithm
The CFA and EFA results supported the hypothesized five-factor conceptual framework and there were no strong arguments for item deletion. In addition, a cautious, conservative approach was taken toward deleting any items because of the skewed response distributions for most items; these skewed response distributions were considered reflective of very high acceptance in this sample rather than an inherent limitation of the instrument. Given the skewed data, it was considered prudent to err on the side of caution by retaining items at this point, rather than risk deleting items that may have importance in other study populations. Deletion of item 15 ("time to give injection") was considered given the very high correlation with item 14 ("time taken to prepare") (r ¼ 0.91). Nevertheless, the qualitative research during instrument development supported items 14 and 15 being conceptually distinct, and injections for some treatments may take a relatively long time to administer, for example, time it takes to physically inject the medication, which could potentially impact acceptance separately from the time required to prepare an injection [11] . In addition, the factor analysis results provide evidence supporting the item-scale structure of the instrument with all items retained. Therefore, this item was retained pending further testing in future studies with more evenly distributed data to assess the conceptual distinctness of these items. Although only a small proportion of the sample reported side effects, it was agreed that it was important to capture any presence (and resulting impacts) of side effects, and these items were also retained. Even with all items retained, the instrument length (22 items) and time required to complete it (approximately 5-10 minutes for most patients) did not suggest problematic respondent burden. It was also decided that responses from patients who incorrectly followed the skip pattern (e.g., reported "no" side effects or pain but continued to answer the items associated with side effects or pain) should be included in the calculation of the total score on the basis that if patients have taken the time to provide an answer, then it should be included in the data. Nevertheless, because the overall acceptance domain was highly correlated with all other domains apart from the acceptance of side effects domain, it was decided to exclude it from the total score. Therefore, a revised four-factor conceptual framework (excluding the overall acceptance items and including patients who had incorrectly followed the skip pattern) was psychometrically evaluated.
Development of scoring algorithm
Because items in the overall acceptance domain were highly correlated with all domains except the acceptance of side effects domain, they were excluded from the scoring algorithm. Domain scores were then derived as the sum of scores for items answered V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] -] ] ] divided by the total possible score for items answered multiplied by 100. The total score was calculated as follows:
ðPerceived efficacy score þAcceptance of side effects score þ Injection self-efficacy scoreþ Injection convenience scoreÞ 4:
The scores are based on at least 50% of the items being nonmissing. Figure 2 presents the revised conceptual framework for the I-TAQ.
Psychometric Evaluation of the Finalized I-TAQ Using Scoring Algorithm
CFA four-factor results
The CFA and EFA were conducted with a sample of 151 patients and a WLSMV method of estimation was used. The CFA supported the construct validity of the revised four-factor framework ( Fig. 3) , with all items loading highly onto their hypothesized factor (40.70). The correlations among factors were generally small to moderate, ranging from 0.02 (between perceived efficacy and acceptance of side effects) to 0.716 (between injection self-efficacy and injection convenience).
The CFA had acceptable model fit (indicated by RMSEA ¼ 0.066 and CFI ¼ 0.989). For the EFA, the first four factors all had eigenvalues higher than 1 (range 6.895-1.292; the eigenvalue for the fifth factor dropped to 0.797) and a four-factor solution provided the best account of the data (RMSEA ¼ 0.062 and CFI ¼ 0.995) ( Table 2) . Encouragingly, all items also loaded (40.50) on exactly the same factors as in the final CFA. All items loaded most highly on their own factor and did not load at higher than 0.40 on any other factor.
Multitrait analysis
In a multitrait analysis, items in all domains, except the acceptance of side effects domain, surpassed the criterion for item convergent validity (correlations of 40.40 with the item's own domain) ( Table 3 ). All items in the acceptance of side effects domain failed to meet the criterion for item convergent validity, but the small sample size and highly skewed response distributions precluded a definitive assessment of this domain. All items in all domains, apart from the acceptance of side effects domain, met the criterion for item discriminant validity (each item had a higher correlation with the item's own domain than any other domain). The following two items did not demonstrate discriminant validity: item 4 ('acceptance of side effects'; r ¼ 0.31 vs. r ¼ 0.35 with injection convenience domain) and item 6 ('side effects interfere with leisure/free time'; r ¼ 0.31 vs. r ¼ 0.44 with self-efficacy domain). 
Convergent validity
Known-groups analysis
In an exploratory known-groups analysis, I-TAQ scores were compared among different subgroups (Table 3 ). There was a statistically significant difference in mean I-TAQ perceived efficacy scores between patients with HeFH (n ¼ 51) and those without HeFH (n ¼ 90). Patients with HeFH had significantly higher mean perceived efficacy scores (75.7 Ϯ 24.4) than patients without HeFH (65.7 Ϯ 29.4) (P ¼ 0.041). It was expected that patients at very high risk of CV events may have a higher acceptance score than patients at high risk because of the increased perceived benefit of treatment. There were, however, no significant differences in mean scores between patients with high (85.1 Ϯ 10.0) and very high (87.5 Ϯ11.5) CV risk for any of the I-TAQ domains or the total score (P ¼ 0.198).
There was a statistically significant difference in mean I-TAQ perceived efficacy scores between patients using a prefilled pen (65.8 Ϯ 28.2) and those using a prefilled syringe (80.9 Ϯ 23.0) (P o 0.005). The difference in mean scores for the other domains and total score were not statistically significant (P ¼ 0.073-0.697).
It was expected that patients who had higher overall acceptance on the PGI-A would also have higher acceptance scores on the I-TAQ. For all domains and the total score, higher I-TAQ scores were observed for those patients with higher PGI-A scores, with monotonic increases in scores across the three groups (Table 3) . Differences in mean scores for all groups across each domain and total score were statistically significant (P o 0.001).
Discussion
Health care providers and other health care decision makers can have concerns regarding the acceptability of subcutaneous injections for the treatment of chronic and asymptomatic conditions such as elevated LDL-C levels, especially in situations in which oral therapies are common and well established. As such, a valid and reliable measure of treatment acceptance for evaluating treatments is needed to quantify patient acceptance. To address this need, the I-TAQ was developed using methods in line with the present best practice guidance for the development and validation of PRO instruments [16] [17] [18] . Specifically, appropriate, in-depth qualitative work and rigorous psychometric methods were used to ensure the content validity of the I-TAQ.
The results presented here provide encouraging initial evidence of acceptable measurement properties for the I-TAQ in this population of high CV risk patients being treated with a subcutaneous injection for lowering LDL-C levels. Item response distributions were skewed toward the upper end of the scale (indicating high acceptance), but it is likely that this is due to the sample having high acceptance of their treatment and the mode of administration rather than being indicative of a problem with the instrument. This interpretation is consistent with previous qualitative findings in which most patients (n ¼ 28; 97%) reported high acceptance [11] and it is perhaps not surprising given that all participants provided consent to participate in a clinical trial of a subcutaneous treatment. High interitem correlations were identified between a number of item-pairs, including items 14 and 15, assessing the time required to prepare the injection and the time required to take the injection. Such high item correlations are, however, difficult to interpret in the context of the skewed distributions. Moreover, consideration of the qualitative research and the item content suggests that all are conceptually distinct and so all were retained pending further study. Examining Cronbach α for each domain with each item removed in turn found that the removal of only two items would result in a very minor increase in internal reliability-in all other cases Cronbach α decreased. This provides evidence that the items within domain scores are all closely related, are each contributing to the domain score, and that their removal did not improve the reliability of the domain score.
CFA, EFA, and multitrait analysis were conducted to examine the appropriateness of the a priori conceptual framework. Both CFA and EFA results supported the hypothesized five-domain structure, with high factor loadings and minimal cross loading. Nevertheless, because the overall acceptance domain correlated with all domains, it was removed from the calculation of the total score. None of the psychometric or previous qualitative findings supported the deletion of any items and therefore all items were retained. Psychometric evaluation of the resulting I-TAQ scoring algorithm supported the construct validity of the instrument. Factor analysis results supported the scoring algorithm, and multitrait analysis showed that almost all items correlated highly with the domains in which they were included (and more highly than with any other domain) and all domains showed high internal consistency.
Results for concurrent or convergent validity were mixed, and these are again difficult to interpret in the context of the skewed response distributions. For concurrent or convergent validity, there were some moderate correlations with the ACCEPT domains, supporting the convergent validity of the I-TAQ. Other domains expected to correlate did not (i.e., I-TAQ injection convenience and ACCEPT medication inconvenience and regimen constraints; I-TAQ injection self-efficacy and ACCEPT effectiveness; I-TAQ overall acceptance and ACCEPT general acceptance). Nevertheless, this perhaps reflects the fact that the ACCEPT is a generic measure of treatment acceptance (asking about medicines in general) and is not specific to injections, whereas the I-TAQ questions focus specifically on acceptance toward a subcutaneous mode of administration.
Overall, patients taking alirocumab via subcutaneous injection had high acceptance of the treatment. For example, 92.1% of patients found self-injection with the prefilled pen or prefilled Fig. 3 -CFA four-factor structure. Note. Items with standardized coefficients o0.30 would be flagged as candidates for possible deletion. Items 5, 6, and 7 were excluded from this analysis because of low response numbers. Items 3 and 11 were dichotomous gateway items and were also excluded from this analysis. CFA, confirmatory factor analysis. n Mean Ϯ SD P value n Mean Ϯ SD P value n Mean Ϯ SD P value n Mean Ϯ SD P value n Mean Ϯ SD P value n Mean Ϯ SD P value PGI-A response groups:
o0.001 o0.001 o0.001 o0.001 o0.001 syringe to be acceptable or very acceptable, with 94.7% of patients feeling confident in their ability to self-inject alirocumab. It is noted that the analyses of known-groups validity were exploratory with hypotheses having to be made without previous data to guide how acceptance might vary among patient subgroups. Minimal differences in acceptance scores were observed between the groups, with only the perceived efficacy domain demonstrating significant differences in scores for all but one of the analyses. The exception was the comparison of I-TAQ scores among groups defined by PGI-A responses in which differences in mean scores for all domains and the total score were statistically significant (P o 0.001). It must be acknowledged that it would have been preferable to use a validated measure of overall acceptance to define groups rather than the PGI-A, which was developed specifically for this study (i.e., it could be regarded as slightly circular that validity of the newly developed measure was evaluated against a global item that has not itself been validated). Nevertheless, because no such measure was identified, the PGI-A was developed to facilitate a known-groups comparison, and we suggest that the use of global assessments without evidence of validity in psychometric studies is not uncommon. A further limitation is the fact that the groupings of the PGI-A were skewed to reflect the skewed data and ensure there was a sufficient number of patients in each group. In a less skewed data set, the grouping of the PGI-A would be more evenly distributed. Between patients with HeFH and those without HeFH, no differences in acceptance of side effects, perceived self-efficacy, injection convenience, and overall acceptance score were noted, although patients with HeFH reported higher perceived efficacy scores. Likewise, in a comparison of prefilled pen and prefilled syringe, the only significant difference was in the perceived efficacy domain. This was encouraging given it was hypothesized that patients using the prefilled syringe would have lower acceptability scores compared with those using the prefilled pen [19] .Most of the patients using a prefilled syringe (n ¼ 32 of 36; 88.9%), however, were diagnosed with HeFH, and so it is possible that this finding was confounded by the presence of HeFH.
Study Limitations and Further Research
In addition to the limitations noted earlier regarding the PGI-A, several other limitations should be considered when interpreting the results of this study. Some of the patients were enrolled in openlabeled trials and therefore had been receiving alirocumab for a long time before taking part in this study. They reported high treatment acceptance in these trials. Adaptation to treatment may have occurred, but this would also be expected in routine clinical care. As noted previously, this resulted in a lack of variation in response distributions, with responses skewed toward the positive end of the scale, which should be considered when interpreting all results.
Furthermore, very few patients reported side effects, therefore resulting in only a small sample responding to these items, which limited the assessment of the side effects domain. Assessing psychometric properties of the measure in a population in which greater distributions of responses are expected and in populations more recently exposed to treatment that may also have side effects is recommended to further evaluate the psychometric properties of the I-TAQ. Given the multidimensional nature of the I-TAQ, a modern psychometric model such as Rasch or item response theory was not considered appropriate during this study. Nevertheless, the use of such methods to evaluate the dimensionality within the domains of the I-TAQ could be considered in the future.
The qualitative results supported an a priori conceptual framework that provided rationale to conduct CFA. Because of the skewed data, EFA was also conducted to further explore whether other item-scale structures should be considered. It would have been preferable to conduct the CFA and EFA in different samples, and indeed to then perform the evaluation of the instrument properties in a separate sample. This was not possible with the data presently available, but it is recommended that further evaluation be performed in future studies.
The I-TAQ has been developed as a measure of treatment acceptance related to taking an injectable treatment in a clinical trial. Although the I-TAQ measures concepts that would potentially be relevant to other patient populations in which treatment is selfadministered via injection, further content validity and psychometric evaluation in other patient populations would be required to support wider use. It is also acknowledged that the I-TAQ was developed for use in clinical trials and there are limitations in generalizing data collected to real-world experience of injection treatments. Again, further evaluation in a real-world population is necessary to confirm the instrument's applicability in that context of use. Similarly, participants were recruited from studies that were close to completion; therefore, it was not possible to administer the instrument at two time points to support the evaluation of testretest reliability. Furthermore, no insights into the responsiveness of the measure to alternative strategies (prefilled syringes vs. prefilled pens) or educational interventions were explored and so should be assessed in future studies. Finally, the measure has been evaluated only in US-English-speaking populations; it is recommended that further validation be performed in other languages and cultures to confirm cross-cultural validity of the instrument. In summary, although the present results are encouraging, there is much further work that could be performed.
Conclusions
These findings provide initial evidence that the I-TAQ has acceptable psychometric properties in patients with high CV risk treated with subcutaneous alirocumab. Results provide evidence of acceptable reliability and construct validity as a measure of patientreported treatment acceptance in this specific population, with the potential to provide a valuable PRO for evaluating patients' acceptance of therapies requiring subcutaneous injection.
